CJC-1295 vs Sermorelin
CJC-1295 and Sermorelin are both GHRH analogs that stimulate growth hormone release through the same receptor pathway. The key difference is that Sermorelin was the first GHRH analog with decades of clinical use, while CJC-1295 is a newer modified version designed for a much longer half-life.
Side-by-Side Comparison
| Category | CJC-1295 | Sermorelin |
|---|---|---|
| Mechanism of action | Modified GHRH analog with Drug Affinity Complex (DAC) that binds albumin, extending half-life to ~8 days. Provides sustained GHRH receptor stimulation and continuous GH/IGF-1 elevation. | GHRH(1-29) analog (the bioactive portion of natural GHRH). Short half-life (~10-20 minutes). Mimics natural pulsatile GH release pattern more closely. |
| Primary research area | Sustained GH elevation, body composition, anti-aging. Developed by ConjuChem for once-weekly dosing convenience. | GH deficiency in children and adults. Was FDA-approved (Geref, 1997) for diagnostic use and GH deficiency in children, but discontinued commercially in 2008. |
| Evidence level | Phase II clinical trials. Published human PK data showing sustained IGF-1 elevation. Not FDA-approved. Relatively newer with less long-term safety data. | Previously FDA-approved (Geref). Decades of clinical use and safety data. Well-characterized pharmacology. The most studied GHRH analog historically. |
| Administration route | Subcutaneous injection. DAC version: once weekly. No-DAC: 1-3x daily. | Subcutaneous injection, typically once daily before bed. |
| Typical research dosing | DAC: 2 mg once weekly. No-DAC: 100 mcg 1-3x daily. | 100-300 mcg daily subcutaneous, typically before bed. 3-6 month cycles. |
| Key studies/evidence | Teichman et al. (2006) — human PK study. ConjuChem phase II data. Sustained IGF-1 elevation demonstrated over multiple days. | Decades of published literature. FDA approval history (Geref). Walker et al. — long-term safety and efficacy in GH-deficient children. Largest safety dataset among GHRH analogs. |
Can They Be Stacked?
Generally not combined since they act on the same GHRH receptor. Using both would be redundant. Choose one GHRH analog and optionally pair with a GHRP (like Ipamorelin) for synergistic GH release through complementary pathways.
Verdict
Sermorelin has the strongest safety track record among GHRH analogs due to its prior FDA approval and decades of clinical use. CJC-1295 DAC offers the convenience of weekly dosing and sustained GH elevation, but has less long-term safety data. Sermorelin more closely mimics natural pulsatile GH release, which some researchers consider more physiological. CJC-1295 DAC's continuous elevation may be advantageous or problematic depending on the goal.
Related Comparisons
CJC-1295 and Ipamorelin are both growth hormone secretagogues, but they work through different receptor pathways. CJC-1295 is a GHRH (growth hormone-releasing hormone) analog, while Ipamorelin is a growth hormone-releasing peptide (GHRP). They are frequently combined rather than used as alternatives.
MK-677 vs CJC-1295MK-677 (Ibutamoren) and CJC-1295 both elevate growth hormone levels, but through entirely different mechanisms and routes. MK-677 is technically not a peptide -- it's a non-peptide ghrelin mimetic taken orally. CJC-1295 is a GHRH analog that requires injection. This distinction significantly affects their use profiles.
Sermorelin vs Tesamorelin: GH Peptide ComparisonSermorelin and Tesamorelin are both GHRH (growth hormone-releasing hormone) analogs that stimulate the pituitary gland to produce growth hormone. Despite sharing the same fundamental mechanism, they differ significantly in regulatory status, clinical evidence, half-life, and cost. Sermorelin is a well-known compounded peptide with decades of use, while Tesamorelin is the only GHRH analog currently holding active FDA approval -- specifically for HIV-associated lipodystrophy.
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Peptides are biologically active compounds that carry risks. Consult a healthcare provider before using any peptides. Many peptides discussed here have limited human clinical data — always verify current research status before making decisions.